Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
By sharing this study design, we hope to inform on the lessons learned from operationalizing a global study evaluating durable ART-free viral control, including the critical role of engaging members of the HIV community during clinical trial design to ensure the success of an ATI-inclusive study.
Authors
- Jeff Berry
- Jacob Lalezari (ORCID: https://orcid.org/0000-0002-2744-4918)
- Andrew Topp
- Simiso Mandisa Sokhela (ORCID: https://orcid.org/0000-0002-2707-1533)
- Manal Abunimeh
- Gary Sinclair
- Preethi Krishnan (ORCID: https://orcid.org/0000-0002-2296-4594)
- Beatriz Mothe (ORCID: https://orcid.org/0000-0001-9975-407X)
- Jean‐Pierre Routy
- Sharon R. Lewin (ORCID: https://orcid.org/0000-0002-0330-8241)
- Siegfried Schwarze
- Karine Dubé
- Ricardo Sobhie Diaz (ORCID: https://orcid.org/0000-0002-8395-7304)
- Daniel E. Cohen (ORCID: https://orcid.org/0000-0002-7911-227X)
- Ana Gabriela Pires dos Santos
- Sarah Gill
Institutions
- University of the Witwatersrand (ZA)
- University of Reunion Island (RE)
- McGill University Health Centre (CA)
- AbbVie (United States) (US)
- University of California San Diego (US)
- Quest Clinical Research (United States) (US)
- Proteogenomics Research Institute for Systems Medicine (US)
- Peter Doherty Institute (AU)
- V-Projekt (Czechia) (CZ)
- Hospital Universitari Germans Trias i Pujol (ES)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Contemporary Clinical Trials
- Published
- 2025-11-09
- DOI
- https://doi.org/10.1016/j.cct.2025.108144
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00